Table 2.
Baseline characteristics and outcomes of the cumulative group and by cohort (N = 142)
| Characteristics | n (%) | |||||
|---|---|---|---|---|---|---|
| All (N = 142) | Cumulative control (N = 106) | Isingiro 2011 (N = 40) | Isingiro 2012 (N = 32) | MVP 2011 (N = 34) | MVP 2012 (N = 36)* | |
| Sex | ||||||
| Male | 104 (73.2) | 79 (74.5) | 30 (75.0) | 23 (71.9) | 26 (76.5) | 25 (69.4) |
| Female | 36 (25.4) | 27 (25.5) | 10 (25.0) | 9 (28.1) | 8 (23.5) | 9 (25.0) |
| Unknown | 2 (1.4) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (5.6) |
| Age | ||||||
| 25% | 30 | 30 | 31 | 30 | 31 | 28 |
| Median | 40 | 40 | 39.5 | 38.5 | 41 | 40 |
| 75% | 49 | 48 | 49 | 45.5 | 46 | 52 |
| Patient category | ||||||
| New | 122 (85.9) | 95 (89.6) | 35 (87.5) | 28 (87.5) | 32 (94.1) | 27 (75) |
| Retreatment† | 18 (12.7) | 10 (9.4) | 4 (10) | 4 (12.5) | 2 (5.9) | 8 (22.2) |
| Unknown | 2 (1.4) | 1 (0.9) | 1 (2.5) | 0 (0) | 0 (0) | 1 (2.8) |
| Type of tuberculosis | ||||||
| Pulmonary, sputum positive | 113 (79.6) | 87 (82.1) | 36 (90.0) | 27 (84.4) | 24 (70.6) | 26 (82.2) |
| Pulmonary, sputum negative | 19 (13.4) | 13 (12.3) | 2 (5.0) | 1 (3.1) | 10 (29.4) | 6 (16.7) |
| Extra-pulmonary | 8 (4.9) | 6 (5.7) | 2 (5.0) | 4 (12.5) | 0 (0) | 2 (5.6) |
| Unknown | 2 (2.1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (5.6) |
| HIV status | ||||||
| HIV-positive | 55 (38.7) | 43 (40.6) | 15 (37.5) | 12 (37.5) | 16 (47.0) | 12 (33.3) |
| HIV-negative | 80 (56.3) | 60 (56.6) | 24 (60.0) | 20 (62.5) | 16 (47.0) | 22 (61.1) |
| Unknown | 8 (4.9) | 3 (2.8) | 1 (2.5) | 0 (0) | 2 (5.9) | 2 (5.6) |
| Patient knows HIV status and received counseling | ||||||
| Yes | 132 (93.0) | 100 (94.3) | 36 (90.0) | 32 (100) | 32 (94.1) | 34 (94.4) |
| No | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Unknown | 10 (7.0) | 6 (5.7) | 4 (10.0) | 0 (0) | 2 (5.9) | 2 (5.6) |
| Enrolled on CPT, where applicable (% total/percentage of applicable) | ||||||
| Yes | 52 (36.6/94.5) | 40 (37.7/93.0) | 15 (37.5/100) | 11 (34.4/91.7) | 14 (41.2/87.5) | 12 (33.3/100) |
| No | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Unknown | 3 (2.1/5.5) | 3 (2.8/7.0) | 0 (0) | 1 (3.1/8.3) | 2 (5.9/12.5) | 0 (0) |
| Enrolled on ART, where applicable (% total/percentage of applicable) | ||||||
| Yes | 21(14.8/38.2) | 17 (16.0/39.5) | 8 (20.0/53.3) | 5 (15.6/41.7) | 4 (11.8/25.0) | 4 (33.3/11.1) |
| No | 2 (1.4/3.6) | 1 (0.1/2.3) | 0 (0) | 0 (0) | 1 (2.9/6.3) | 1 (2.8/8.3) |
| Unknown | 32 (22.5/40.0) | 25 (23.5/58.1) | 7 (17.5/46.7) | 7 (21.9/58.3) | 11 (32.4/68.8) | 7 (19.4/5.8) |
| Outcome | ||||||
| Cured | 48 (33.8) | 30 (28.3) | 13 (32.5) | 6 (18.8) | 11 (32.4) | 20 (55.6) |
| Success | 108 (76.1) | 79 (74.5) | 28 (70.0) | 26 (81.3) | 25 (73.5) | 29 (80.6) |
| Transfer | 16 (11.3) | 9 (8.5) | 5 (12.5) | 3 (9.4) | 1 (2.9) | 7 (19.4) |
| Failure | 1 (0.01) | 1 (0.9) | 0 (0) | 1 (3.1) | 0 (0) | 0 (0) |
| Lost to follow-up | 8 (5.6) | 8 (7.6) | 5 (12.5) | 0 (0) | 3 (8.8) | 0 (0) |
| Died | 9 (6.3) | 9 (8.5) | 2 (5) | 2 (6.3) | 5 (14.7) | 0 (0) |
| Negative outcome | 18 (12.7) | 18 (17) | 7 (17.5) | 3 (9.4) | 8 (23.5) | 0 (0) |
Enrolled on eCompliance.
Retreatment, a patient who is returning after default, or receiving retreatment after initial treatment failure, or who has relapsed; for outcome definitions see Table 1.
Isingiro 2011 represents those patients enrolled on manually recorded DOTS at clinics outside of the MVP cluster in 2011; Isingiro 2012 represents those patients enrolled on manually recorded DOTS at clinics outside of the MVP cluster in 2012; MVP 2011 represents those patients enrolled on manually recorded DOTS at clinics inside the MVP cluster in 2011; MVP 2012 represents those patients enrolled on DOTS at clinics in the MVP cluster in 2012 where eCompliance was used as the method of recording observations; and cumulative control represents the composite of Isingiro 2011, Isingiro 2012, and MVP 2011.